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Abstract
Little is known about how ophthalmologist-
patient communication over time is associated
with glaucoma patient long-term adherence.
The purpose of our study was to examine the as-
sociation between provider use of components of
the resources and supports in self-management
model when communicating with patients and
adherence to glaucoma medications measured
electronically over an 8-month period. In this
longitudinal prospective cohort study, the main
variables studied were ophthalmologist commu-
nication-individualized assessment, collaborative
goal setting and skills enhancement. Patients with
glaucoma who were newly prescribed or on glau-
coma medications were recruited from six oph-
thalmology clinics. Patients’ baseline and next
follow-up visits were videotape-recorded.
Patients were interviewed after their visits.
Patients used medication event monitoring sys-
tems (MEMS) for 8 months after enrollment
into the study, and adherence was measured elec-
tronically using MEMS for 240 days after their
visits. Two hundred and seventy-nine patients
participated. Patient race and regimen complex-
ity were negatively associated with glaucoma
medication adherence over an 8-month period.
Provider communication behaviors, including
providing education and positive reinforcement,
can improve patient adherence to glaucoma
medications over an 8-month period.
Introduction
Glaucoma is similar to high blood pressure in that it
is a chronic asymptomatic disease. Yet glaucoma
differs from other chronic diseases in that rather
than taking oral medications, most patients need to
instill eye drops long term with the ultimate goal of
reducing intraocular pressure to preserve vision [1].
Prior work has found that non-adherence to using
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glaucoma medications is a significant problem and
thus a concern for vision loss from glaucoma [2–7].
Adherence to medications is a critical self-
management behavior for a chronic condition like
glaucoma. One framework that has been applied to
improving self-management behavior in individuals
with chronic diseases is the resources and supports
for self-management [8]. This framework uses key
provider communication behaviors including indi-
vidualized assessment, collaborative goal setting
and skills enhancement that are important for pro-
viders to engage in when interacting with patients
with chronic disease to improve self-management
skills. We applied this framework to examine how
key provider communication behaviors were asso-
ciated with long-term adherence to glaucoma medi-
cation over an 8-month period.
Individualized assessment involves exploring the
patient’s personal and cultural perspective on the
chronic disease and how it impacts their life [8, 9].
It is important for ophthalmologists to conduct an
individualized assessment with glaucoma patients
so that they can better understand patients’ views
of glaucoma and glaucoma medication treatment
options since each topical class of medications dif-
fers from other classes [2–4, 6, 10].
Collaborative goal setting involves empowering
patients and asking for their input when treatment
decisions are being made [8]. Collaborative goal
setting has been examined in several different dis-
ease states such as cardiac rehabilitation, asthma,
osteoporosis, psychiatry and diabetes [11–16]. In a
prior study involving 51 patients who were newly
diagnosed and prescribed glaucoma medications,
we found that collaborative goal setting occurred
infrequently [17].
Skills enhancement involves physicians provid-
ing information required for glaucoma self-manage-
ment and encouraging and reinforcing positive
patient behaviors [18]. It is important for ophthal-
mologists to educate patients about glaucoma so that
patients understand why they are taking glaucoma
medication. Additionally, ophthalmologists need to
educate patients about the medications they are
taking so that patients understand how to use them
appropriately. At the same time as providing
education to patients, ophthalmologists also need
to motivate patients to adhere to their medications
and give them positive reinforcement on their medi-
cation-taking.
Therefore, the purpose of our study was to (i)
describe the extent to which providers use compo-
nents of the resources and supports in self-
management model (individualized assessment,
collaborative goal setting and skills enhancement)
when interacting with patients across time and (ii)
examine the association between provider use of
components of the resources and support in self-
management model when communicating with
patients and patient adherence to glaucoma medica-
tions measured electronically over an 8-month
period based on assessment of percent doses taken
over 240-day period, percent correct number of
doses taken each day, and percent prescribed doses
taken on time.
Methods
Procedure
This study, approved by the Institutional Review
Boards at the University of North Carolina, Duke
University, Emory University and the University of
Utah, was HIPAA compliant. English-speaking
adult glaucoma patients were enrolled at six geo-
graphically distinct ophthalmology clinics located
in four states. Two sites were private offices and
four were affiliated with academic ophthalmology
departments. At each site, clinic staff referred eli-
gible patients to research assistants who were based
at the clinics. Written patient and provider consent
was obtained. Providers completed a short demo-
graphic questionnaire after providing consent.
Participants had their medical visit videotape-
recorded when they enrolled into the study.
Videotapes were kept if they fit one of two criteria:
(i) the patient was diagnosed with glaucoma and
glaucoma medications were prescribed for the
first time or (ii) patients were already taking
glaucoma medications. Patients who met either of
these criteria were followed for the 8-month study
period.
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Patients were interviewed after their medical
visits. The patient’s glaucoma eye drops were
placed into large prescription vials with medication
event monitoring system (MEMS) caps on top
which electronically assessed patient adherence
[3]. The patient’s next glaucoma visit was also
video-tape recorded. Patients used the MEMS caps
for 8 months after their baseline video-taped visit.
The patient’s next follow-up visit, which typically
occurred four to six weeks later, was also video-
taped recorded.
Measurement
Personal characteristics
Self-reported patient race was measured as a cat-
egorical variable (White, African American,
Asian, Native American and Hispanic) and then
recoded into African American and non-African
American. The majority of the non-African
American patient sample was White (91%). The
number of glaucoma medications a participant was
taking was recorded. Whether the patient was pre-
scribed glaucoma medication for the first time
during the medical visit or was already on glaucoma
medication before the visit was also recorded.
Each participant received the rapid estimate of
adult literacy in medicine (REALM). This is a vali-
dated, rapid screening instrument designed to iden-
tify patients who have difficulty reading common
medical and lay terms that are routinely used in pa-
tient education materials [19]. We chose the
REALM because it has high face validity and high
criterion validity, it has been well received by pa-
tients, and it only takes 2–3 min to administer and
score [19]. Patient scores on the REALM corres-
pond to reading levels (score of 0–60¼ eighth
grade and below, 61–66¼ ninth grade and above).
Physicians reported their age, gender and race
(White, African American, Asian, Native
American and Hispanic).
All participants were administered a 10-item gen-
eral glaucoma medication adherence self-efficacy
questionnaire and a 6-item eye drop technique
self-efficacy scale [20, 21]. Patients were given
three possible response choices for the self-efficacy
items: not at all confident (coded as 1), somewhat
confident (coded as 2) and very confident (coded as
3). Scores on the glaucoma medication adherence
scale could range from 3 (lower self-efficacy) to 30
(higher self-efficacy). The scale had a Cronbach’s
alpha of 0.94. Scores on the eye drop technique self-
efficacy scale could range from 3 (lower self-
efficacy) to 18 (higher self-efficacy). The scale had
a Cronbach’s alpha of 0.88. Both of the self-efficacy
scales have strong psychometric properties [20, 21].
Outcome expectations were measured using four
items designed to assess how much patients believed
attending their ophthalmic clinical visits and taking
medications would help their glaucoma and
vision [20]. Responses ranged from 1 (not at all)
to 9 (extremely) for each item. Scores could range
from 4 to 36 on the outcome expectations scale. The
scale had a Cronbach’s alpha of 0.94 in the current
sample.
Communication measures
All of the medical visit video-tapes were transcribed
into text verbatim with identifiers removed. A de-
tailed coding tool was developed over a 1-year per-
iod. The transcripts were reviewed by a research
assistant who met twice a month with the investiga-
tors to develop and refine the coding rules. The tran-
scripts of the medical visits from each time point
were coded. Table I presents the definition of each
coding category.
Using the coding tool for transcribed medical
visits, coders recorded whether the provider edu-
cated the patient in the following areas about glau-
coma: (i) physical changes with glaucoma and/or
how to manage these changes, (ii) emotional
changes with glaucoma and/or how to manage
these changes, (iii) diagnosis, (iv) family history,
(v) goals of treatment, (vi) how to problem solve,
(vii) intraocular pressure, (viii) likelihood of long-
term therapy, (ix) ways to manage glaucoma other
than with medications and (x) prognosis. We
summed the total number of areas educated about
at each visit. We then added these two variables
together to create ‘total amount of glaucoma educa-
tion provided across both visits’.
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Table I. Definitions of the coding variables
Coding category Definition
Glaucoma
Physical changes that can occur with
glaucoma and/or how to manage
these changes
This includes education about the physical changes associated with glaucoma and
how to manage physical changes that can occur with glaucoma.
Emotional changes that can occur with
glaucoma and/or how to manage
these changes
This includes education about the emotional difficulty of having glaucoma, loss of
vision, depression, or anxiety and how to manage emotional changes that can
occur with glaucoma.
Diagnosis This includes education about what glaucoma is.
Family history This includes education about family history being a risk factor for glaucoma.
Goals of treatment This includes education about what the goals of treatment are to prevent vision
loss.
How to problem solve This includes provider giving advice on how the patient can problem solve if he or
she runs into trouble with managing their glaucoma.
Intraocular pressure This includes education about what intraocular pressure (IOP) is.
Likelihood of long-term therapy This includes education about glaucoma being a chronic condition that requires
long-term therapy.
Management plan (ways to manage
glaucoma without medications)
This includes education about other ways to manage glaucoma other than medica-
tions (e.g. surgery).
Prognosis This includes education about the patient’s prognosis, how the patient is doing, and
the potential for vision loss.
Glaucoma medications
Adherence and adherence strategies This includes education about adherence, missed doses, and/or extra doses taken.
Amount/dose (number of drops) This includes education about the number of drops to take each time.
Cost/insurance This includes education about the cost of medications, prescription drug insurance,
and/or drug assistance programs.
Eyelid closure and nasolacrimal occlu-
sion when applying topical
medications
This includes education about how to improve absorption of the medication or
reduce local side effects.
Fear/concerns/barriers This includes education about any fears or concerns (real or perceived) about the
medications the patient is currently taking or will be taking in the future.
Frequency of use This includes education about how often a medication should be used on a daily
basis. Also, it includes when it should be used before, during, or after certain
situations.
Generic/brand This includes education about the equivalence of medications (brand and generic)
or whether the medicine that is being prescribed is available as a generic or
brand name.
How well medication is working This includes education about how well the medication works, and how effective it
is or is not.
How to administer This includes education about how to administer eye drops. Also, it includes educa-
tion about the amount of time to wait between administering two or more eye
drop medications.
Side effects This includes education about side effects of medication (real or perceived), as well
as doctor offering explanations or reassurances about possible side effects brought
up by patient.
Importance of use This includes education about why the glaucoma medication is important to use.
Last time used drops This includes information about the last time the patient used eye drops and how it
relates to current IOP reading.
Length of use This includes education about how long the patient will need to use the medicine.
Name of medication This includes discussion about the name of the medication that the patient is
prescribed.
(continued)
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Coders also recorded whether the provider
educated the patient in the following areas
about glaucoma medications: (i) adherence and
adherence strategies, (ii) amount/dose, (iii) cost/
insurance, (iv) eyelid closure and nasolacrimal
occlusion when applying topical medications,
(v) fear/concerns/barriers, (vi) frequency of
use, (vii) generic/brand, (viii) how well medica-
tion is working, (ix) how to administer, (x) side
effects, (xi) importance of use, (xii) last time
used drops, (xiii) length of use, (xiv) name of
medication, (xv) non-glaucoma medications,
(xvi) purpose, (xvii) supply and (xviii) which
eye to install the drops. We summed the total
number of areas educated about at each visit.
We then added these two variables together to
create ‘total amount of glaucoma medication
education provided across both visits’.
Coders recorded whether the provider conducted
the following aspects of an individualized assess-
ment: (i) asks the patient about their views of glau-
coma and/or its treatment, (ii) asks the patient about
how glaucoma will impact their life, (iii) asks about
confidence in using glaucoma medication regularly
and (iv) asks about intention to adhere to glaucoma
medications in the future. For the multivariate ana-
lysis, we summed the total number of aspects of
individualized assessment the provider performed.
However, individualized assessment occurred so in-
frequently that we created a dichotomous variable
‘provider performed an individualized assessment
during one or both visits’.
Table I. Continued
Coding category Definition
Non-glaucoma medications This includes any education of non-glaucoma medications, like steroid eye drops,
Latisse, high blood pressure medicines, or cold medications.
Purpose This includes education about the purpose of the eye drops (e.g. lowers IOP, etc.).
Supply This includes education about how much medication the provider will prescribe,
how long each bottle should last, how to keep track of how many doses are re-
maining in the bottle, and when they may need refills.
Which eye Includes information about which eye to administer the drops.
Individualized assessment
Asks the patient about view of glau-
coma or its treatment
This occurs when the provider asks the patient about his or her views on glaucoma
or its treatment.
Asks the patient about how glaucoma
will impact his or her life
This occurs when the provider asks the patient about how glaucoma will impact
his or her life.
Asks about confidence in using medica-
tion regularly
This occurs when the provider asks about confidence in using glaucoma medication
regularly.
Asks about intention to adhere in the
future
This occurs when the provider asks the patient about his/her intention to adhere to
glaucoma medications in the future.
Collaborative goal setting
Patient is given choices about treatment This occurs when the provider presents one or more treatment options to the
patient.
Provider asks for preferences or ideas
on treatment
This occurs when the provider asks for preferences or ideas on treatment.
Provider asks patient to talk about treat-
ment goals
This occurs when the provider asks the patient to talk about treatment goals.
Patient helps set treatment goals This occurs when the patient helps set treatment goals
Encouragement/reinforcement
Encourages patient to take their glau-
coma medications
This occurs when the provider encourages the patient to take their glaucoma
medications.
Encourages patient to regularly come to
their appointment
This occurs when the provider encourages the patient to regularly come to their
appointments.
Gives positive reinforcement about
glaucoma medication-taking
This occurs when the provider gives the patient positive reinforcement about the
patient’s glaucoma medication-taking.
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Coders recorded whether the provider partici-
pated in the following aspects of collaborative
goal setting: (i) patient is given choices about treat-
ment, (ii) provider asks for preferences or ideas on
treatment, (iii) provider asks patient to talk about
treatment goals and (iv) patient helps set treatment
goals. For the multivariate analysis, we summed the
total numbers of aspects of collaborative goal setting
the provider performed. However, collaborative
goal setting occurred so infrequently that we created
a dichotomous variable ‘provider engaged in collab-
orative goal setting in one or both visits’.
Additionally, coders recorded if the ophthalmolo-
gist encouraged the patient to take their glaucoma
medications and encouraged the patient to regularly
come to their appointments. Coders also recorded
whether the provider gave the patient positive re-
inforcement about the patient’s glaucoma medica-
tion-taking.
Two clinics had ophthalmology fellows see some
of the enrolled patients while two other clinics also
had ophthalmic technicians see some of the enrolled
patients. Informed consent was obtained from these
providers as well. If any one of these providers,
including the physician, educated the patient, it
was counted as education in the categories discussed
earlier.
Three research assistants coded 25 of the same
transcripts throughout the study period to assess
inter-rater reliability which was calculated using
inter-rater correlations. Inter-rater reliability for the
variables ranged from 0.70 to 1.0. If there was not
enough variability to calculate reliability, we calcu-
lated percent agreement between the coders; percent
agreement was 100% for these variables.
Adherence measures
Medication adherence over an 8-month period after
the video-taped visit was evaluated via electronic
data from the MEMS caps system (MeadWestvaco
AARDEX) [3]. Whether the patient took 80% or
more of their prescribed doses was measured from
the MEMS caps using the following formula: adher-
ence ¼ (number of doses used during the past 8
months divided by the number of prescribed
doses) multiplied by 100. We dichotomized the vari-
able since it was skewed toward patients being
highly adherent. Participants were considered adher-
ent if they used 80% or more of the prescribed doses
(79.5% or above was rounded to 80% or more) and
they were classified as non-adherent if they used
<80% of the prescribed doses as suggested in
prior research [23].
We also used the electronic data from the MEMS
caps to examine the percent of doses taken on time
during the 8-month period after the video-taped
visits [3]. If patients were on once a day dosing,
taking it on time was taking it every 24 h plus or
minus 6 h. If it was twice a day dosing, taking it on
time was every 12 h plus or minus 4 h. We also
examined using the MEMS data the percent of cor-
rect number of prescribed doses taken each day
during the 8-month period after the video-taped
visit [3]. We dichotomized these adherence meas-
ures since they were skewed toward patients being
highly adherent. Participants were considered adher-
ent if they used 80% or more of the prescribed doses
(79.5% or above was rounded to 80% or more) on
time and if they took the correct number of doses
each day 80% or more of the time.
If the participant was on more than one glaucoma
medication, an adherence measure was created for
each medication and then an overall adherence vari-
able was created by adding together the participant’s
adherence for each glaucoma medication and divid-
ing it by the number of glaucoma medications the
participant was using. This was done for each of the
three adherence measures.
Analysis
We set the a priori level of statistical significance at
P< 0.05. First, we ran descriptive statistics. Second,
we examined the bivariate relationships between
variables using Pearson correlation coefficients,
chi-square statistics and t-tests as appropriate. We
conducted generalized estimating equations (GEEs)
to examine how patient age, gender, race, glaucoma
medication adherence self-efficacy, glaucoma out-
come expectations, whether the patient was newly
prescribed glaucoma medication on the day of the
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baseline video-taped visit, number of glaucoma
medications the patient was on, provider engaged
in collaborative goal setting at one or both visits,
provider conducted an individualized assessment
at one or both visits, provider encouraged patient
to take medications at one or more visits, provider
gave positive reinforcement about glaucoma medi-
cation taking at one or both visits, total amount of
glaucoma medication education provided at both
visits, total amount of glaucoma education provided
at both visits, physician age and physician gender
were associated with: (i) whether the patient was
80% or more adherent to their glaucoma medica-
tions, (ii) whether the patient took 80% or more of
their doses on time and (iii) whether patients took
the correct number of doses each day 80% or more
of the time according to the MEMS caps during the
240-day period after the video-taped visit. Physician
race could not be included in the multivariable ana-
lysis because there was only one non-White
physician.
Results
Fifteen physicians who cared for glaucoma patients
agreed to participate in the study; one physician
refused to participate for a participation rate of
94%. Fourteen physicians were White and one was
African American. Ten physicians were male
(66.7%). Physician age ranged from 26 to 66 years
(mean 40.8 years, SD 11.7 years).
Eighty-six percent of eligible patients participated
in the study (N¼ 279). We have useable video-tapes
of the baseline visits for 275 of the 279 patients. Six
patients were lost between their baseline visits and
their next follow-up visit. We had useable video-
tapes of the follow-up visit for 264 of the 273 pa-
tients who returned for follow-up visits.
Table II presents the patient demographics. Forty-
one percent of the sample was male and 35.5% were
African American. Eighteen percent of patients
were prescribed glaucoma medications for the first
time. Eighty-nine percent of the enrolled patients
had MEMS caps data for the 240-day period after
their video-taped visit (N¼ 248). Those who did not
have data either did not return their MEMS caps
(N¼ 24) or if they returned their MEMS caps,
there was not useable data (N¼ 7) (e.g. data was
not downloadable due to hardware problems in the
caps).
Table III presents whether physicians educated
about different aspects of glaucoma at one or both
visits. The areas educated about most often during at
least one of the visits were (i) intraocular pressure
(42%), (ii) the physical changes that occur with
glaucoma (35%) and (iii) the treatment goals of
glaucoma (29%). Very few areas were discussed at
both video-taped visits. Intraocular pressure was dis-
cussed the most, with it being discussed at both visits
for 29% of the patients.
Table III also presents whether physicians edu-
cated about different aspects of glaucoma medica-
tion at one or both visits. The areas educated about
most often during at least one of the visits included
(i) side effects (30%), (ii) adherence and adherence
strategies (26%), (iii) frequency of use (23%), (iv)
purpose (17%) and (v) how to administer (16%).
Physicians almost never educated on any of the
areas about glaucoma medications at both visits.
Table IV presents whether physicians conducted
an individualized assessment and whether they used
collaborative goal setting at one or both visits. The
only areas where physicians conducted an
Table II. Participant characteristics (N¼ 279)
Percent (N)
Gender
Male 40.9 (144)
Female 59.1 (165)
Race
African American 35.5 (99)
Non-African American 64.2 (179)
Newly prescribed glaucoma
medications at visit or was on
glaucoma medication before visit
Newly prescribed at visit 18.3 (51)
Was on glaucoma medications before visit 81.7 (228)
REALM
Eighth grade or lower 14.0 (39)
Ninth grade or higher 84.2 (235)
Age in years (mean ± SD) 65.8 ± 12.8
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individualized assessment at one visit were asks
about confidence in using glaucoma medication
regularly (20%) and asks the patient their point of
view about glaucoma and/or its treatment (8%).
Physicians rarely conducted an individualized as-
sessment in any area at both visits.
The areas in which physicians most often engaged
in collaborative goal setting at one visit were patient
is given choice about treatment (17%) and physician
asks for patient preferences or ideas on treatment
(12%). Physicians rarely engaged in any aspects of
collaborative goal setting during both visits.
Providers rarely encouraged patients to take their
glaucoma medications at both visits and they
rarely gave positive reinforcement about medica-
tion-taking at more than one visit.
Table V presents the results of the generalized
estimating equation predicting whether the patient
was 80% or more adherent during the 240-day
period after the baseline visit. African American
patients were significantly less likely to be adherent
than non-African American patients (odds
ratio¼ 0.29, 95% confidence interval¼ 0.16,
0.52). Patients with higher glaucoma medication ad-
herence self-efficacy were significantly more likely
to be adherent than patients with lower self-efficacy
(odds ratio¼ 1.10, 95% confidence interval¼ 1.02,
1.78). Patients seeing older physicians were signifi-
cantly less likely to be adherent (odds ratio 0.95,
95% confidence interval 0.91, 095).
Interestingly, if providers engaged in collaborative
goal setting with patients at either visit, patients were
significantly less likely to be adherent (odds
ratio¼ 0.54, 95% confidence interval 0.29, 0.98). If
providers gave positive reinforcement about the pa-
tient’s medication taking at one or more visits, patients
were significantly more likely to be adherent (odds
ratio¼ 3.37, 95% confidence interval 1.69, 6.71).
Table VI presents the GEE results predicting
whether patients took their doses on time 80% or
Table III. Areas of education provided about glaucoma and glaucoma medications at the initial and follow-up visits (N¼ 279)
Areas provider educated about Neither visit % (N) One visit % (N) Both visits % (N)
Glaucoma
Physical changes that can occur with
glaucoma and/or how to manage these changes
58.4 (163) 35.1 (98) 6.5 (18)
Emotional changes that can occur with glaucoma
and/or how to manage these changes
99.6 (278) 0.4 (1) 0 (0)
Family history 90.7 (253) 9.3 (26) 0 (0)
Goals of treatment 69.2 (193) 29.0 (81) 1.8 (5)
How to problem solve 96.1 (268) 3.9 (11) 0 (0)
Intraocular pressure 28.3 (79) 42.3 (118) 29.4 (82)
Likelihood of long-term therapy 91.4 (255) 8.2 (23) 0.4 (1)
Management plan (ways to manage
glaucoma without medications)
81.7 (228) 15.8 (44) 2.5 (7)
Glaucoma medications
Adherence and adherence strategies 72.0 (201) 25.8 (72) 2.2 (6)
Amount/dose (number of drops) 93.5 (261) 6.5 (18) 0 (0)
Fears/concerns/barriers 95.0 (265) 4.7 (13) 0.4 (1)
Frequency of use 75.6 (211) 22.9 (64) 1.4 (4)
Generic/brand 88.5 (247) 10.8 (30) 0.7 (2)
How to administer 83.5 (233) 16.1 (45) 0.4 (1)
Side effects 65.9 (184) 30.1 (84) 3.9 (11)
Last time used drops 99.3 (277) 0.4 (1) 0.4 (1)
Length of use 100 (279) 0 (0) 0 (0)
Name of medication 91.4 (255) 8.6 (24) 0 (0)
Purpose 82.4 (230) 17.2 (48) 0.4 (1)
Which eye 89.2 (249) 10.0 (28) 0.7 (2)
B. Sleath et al.
700
more of the time during the 8-month period. African
Americans were significantly less likely to take their
doses on time than non-African Americans (odds
ratio¼ 0.38, 95% confidence interval 0.25, 0.58).
Patients on more glaucoma medications were less
likely to take their doses on time (odds ratio¼ 0.62,
95% confidence interval¼ 0.39, 0.98).
If the provider gave positive reinforcement about
the patient’s medication taking at one or more visits,
the patient was significantly more likely to take their
medications on time (odds ratio¼ 2.8, 95% confi-
dence interval 1.44, 5.43). If providers gave more
glaucoma education during the two visits, patients
were significantly more likely to be adherent (odds
ratio¼ 1.35, 95% confidence interval 1.03, 1.78).
Table VI also presents the GEE results predicting
whether patients took the correct number of doses
each day 80% or more of the time during the 8-
month period. African Americans were significantly
less likely to take the correct number of doses each
day than non-African Americans (odds ratio¼ 0.41,
95% confidence interval 0.27, 0.61). If the provider
engaged in collaborative goal setting with the pa-
tient at one or both visits, the patient was signifi-
cantly less likely to take the correct number of doses
each day (odds ratio¼ 0.44, 95% confidence inter-
val 0.29, 0.65). If the provider encouraged the pa-
tient to take their medication at one or both visits
then the patient was significantly more likely to take
the correct number of doses each day throughout the
8-month period (odds ratio¼ 1.84, 95% confidence
interval 1.24, 2.73). Also, if the provider gave posi-
tive reinforcement to the patient about their medica-
tion taking, the patient was significantly more likely
to take the correct number of doses each day (odds
ratio¼ 2.86, 95% confidence interval 1.76, 4.65).
Discussion
One of our most important findings is that the pro-
vider giving the patient positive reinforcement about
their glaucoma medication taking was significantly
associated with all three measures of adherence.
This finding supports the resources and supports in
self-management framework’s assertion that giving
positive reinforcement to patients can improve their
health behaviors, which in this case was patient
medication taking [8]. In addition, if providers
encouraged the patient to take their glaucoma medi-
cations, then the patient was significantly more
likely to take the correct number of doses each day.
These findings emphasize the importance of pro-
viding positive reinforcement on patient medication
taking. Simple statements such as ‘Alright, sounds
like you’re doing a great job with the drop, so keep it
up’ or ‘You’ve done a very nice job taking your
drops. I’m impressed’ could reinforce their positive
Table IV. Extent to which physicians engaged in individualized assessment, collaborative goal setting, encouragement/reinforce-
ment or providing written/video materials at the initial and follow-up visits (N¼ 279)
Neither visit % (N) One visit % (N) Both visits % (N)
Individualized assessment
Asks patient about view of glaucoma or its treatment 92.5 (258) 7.5 (21) 0 (0)
Asks the patient about how glaucoma will impact his or her life 98.9 (276) 1.1 (3) 0 (0)
Asks about confidence in using medication regularly 79.2 (221) 19.7 (55) 1.1 (3)
Asks about intention to adhere in the future 97.8 (273) 2.2 (6) 0 (0)
Collaborative goal setting
Patient is given choices about treatment 81.4 (227) 16.5 (46) 2.2 (6)
Provider asks for preferences or ideas on treatment 85.7 (239) 11.5 (32) 2.9 (8)
Provider asks patient to talk about treatment goals 100 (279) 0 (0) 0 (0)
Patient helps set treatment goals 99.6 (278) 0.4 (1) 0 (0)
Encouragement / reinforcement
Encourages patient to take their glaucoma medications 69.9 (195) 26.2 (73) 3.9 (11)
Encourages patient to regularly come to their appointment 97.1 (271) 2.9 (8) 0 (0)
Gives positive reinforcement about glaucoma medication-taking 59.1 (165) 33.7 (94) 7.2 (20)
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adherence behavior. The findings also indicate that
encouraging patients to take their glaucoma medi-
cations could improve patient adherence. Provider
could say something like ‘Keep up the good work’,
‘You’ve done great. I want you to keep it up’ or ‘So
try your best to remember to take it. It only works if
you take it.’. Future intervention studies should be
designed to motivate providers to: (i) give patients
positive reinforcement about their glaucoma medi-
cation taking behavior and (ii) encourage patients to
take their glaucoma medications.
Despite the assumption that collaborative goal
setting between providers and patients under the
resources and supports in self-management frame-
work should positively impact patient health behav-
ior, we found that if providers engaged in
collaborative goal setting with patients, then the pa-
tients were less likely to take the correct doses per
day and they were less likely to be 80% or more
adherent over the 8-month period [8]. Perhaps pro-
viders were more likely to engage in collaborative
goal setting with patients who they perceived were
less adherent in an attempt to increase adherence.
An interesting finding was that if providers edu-
cated more about glaucoma then the patients were
significantly more likely to take their glaucoma
medication doses on time. This supports the part
of the resources and supports in self-management
framework which emphasizes the importance of
educating patients about their disease state so they
can better understand their condition and be moti-
vated to self-manage the condition on their own [8].
Our findings suggest that providers should make
sure to educate patients about glaucoma because it
can influence their medication adherence. Future
work should design intervention studies to improve
patient knowledge of their glaucoma.
We found that patients on more glaucoma medi-
cations were less likely to take 80% or more of their
doses on time. Wide fluctuations in intraocular pres-
sure, as would be expected from glaucoma medica-
tion doses taken off schedule, are associated with
greater vision loss in patients with advanced glau-
coma, despite low mean intraocular pressure [24].
Our finding that patients on simpler regimens were
more adherent to their glaucoma medications is
similar to what other researchers have found previ-
ously [3, 25, 26]. This suggests that ophthalmolo-
gists might want to simplify glaucoma patients’
medication regimens, if possible, so they have to
take fewer medications each day.
Additionally, even after controlling for provider-
patient communication, African American patients
were significantly less adherent to their medications
on all three measures over the 8-month period. Prior
studies that have examined the relationship between
African American race and adherence to glaucoma
medications have had contradictory results [6, 21,
27–30]. Despite the contradictory prior results, our
Table V. Multivariable generalized estimating equation results
predicting whether the patient is 80% or more adherent during
the 240-day period after the visit according to MEMS caps
(N¼ 239)
Independent variables
Patient is 80% or more
adherent OR (95% CI)
Patient age 0.99 (0.96, 1.02)
Patient gender-female 1.21 (0.59, 2.46)
Patient race-African American 0.29 (0.16, 0.52)***
Glaucoma medication adherence
self-efficacy 1.10 (1.02, 1.78)*
Eye drop technique self-efficacy 0.98 (0.81, 1.19)
Glaucoma outcome expectations 1.15 (1.03, 1.29)*
Newly prescribed glaucoma
medications
0.64 (0.25, 1.65)
Number of glaucoma medications 0.98 (0.51, 1.89)
Provider engages patient
in collaborative
goal setting at one or both visits 0.54 (0.29, 0.98)*
Provider conducts an
individualized assessment
at one or both visits 1.23 (0.68, 2.23)
Provider encourages patient to
take medications
at one or both visits 1.11 (0.46, 2.71)
Provider gives positive
reinforcement about
glaucoma medication taking 3.37 (1.69, 6.71)***
Total amount of glaucoma medication
education provided at both visits 0.89 (0.71, 1.11)
Total amount of glaucoma education
provided at both visits 1.09 (0.84, 1.42)
Physician age 0.95 (0.91, 0.99)**
Physician gender-female 0.50 (0.15, 1.63)
OR, Odds Ratio; 95%CI, 95%, Confidence Interval.
*P< 0.05, **P< 0.01, ***P< 0.001.
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findings suggest that ophthalmologists should make
sure to communicate with African American pa-
tients about what health beliefs or problems are pre-
venting them from being adherent to their glaucoma
medications. Future research is needed to better
understand why patient race is significantly asso-
ciated with medication adherence even after control-
ling for other personal and cultural characteristics
and provider-patient communication.
Our study was the first longitudinal study to
examine ophthalmologist-patient communication
across two visits, prior research has only examined
one visit [22, 27, 31, 32]. One of the most interesting
findings from our work is that providers very rarely
provide education about glaucoma or glaucoma
medication areas during two consecutive visits,
with the exception of intraocular pressure which
was discussed at both visits for less than one-third
of the patients. However, only discussing intraocular
pressure with less than one-third of patients at both
visits is concerning, because one of the main goals
of glaucoma treatment is to lower intraocular pres-
sure. Therefore, it is important for providers to
discuss what a patient’s intraocular pressure is at
each visit so that patients know what their pressure
is and why lowering intraocular pressure is
important.
This study has several limitations. Providers and
patients both knew the visit was being recorded but
they did not know the study hypotheses. Our study is
limited in that we could not track the characteristics
of non-participants so we cannot compare the char-
acteristics of participants and non-participants.
Thus, we cannot estimate selection bias and how
that might impact the generalizability of our results.
Additionally, our coders counted the patient being
educated about glaucoma or glaucoma medications
during visits regardless of whether a physician, tech-
nician or fellow provided it, which limits our ability
to examine differences in education by provider
type. A limitation is that we coded the data this
way so we cannot separate out physician, technician
and fellow provision of education. Another limita-
tion of our study is the lack of variation in physician
race and how provider race might affect physician-
patient communication and adherence.
Table VI. Multivariable generalized estimating equations predicting the percent doses taken on time and the percent correct
number of doses taken each day during the 240-day period after the visit according to MEMS caps (N¼ 239)
Independent variables
Percent doses
Taken on time
OR (95% CI)
Percent correct
number of doses
taken each day
OR (95% CI)
Patient age 1.00 (0.98, 1.03) 1.00 (0.97, 1.03)
Patient gender-female 1.43 (0.65, 3.16) 1.28 (0.75, 2.20)
Patient race-African American 0.38 (0.25, 0.58)*** 0.41 (0.27, 0.61)***
Glaucoma medication adherence self-efficacy 1.00 (0.92, 1.09) 0.99 (0.96, 1.03)
Eye drop technique self-efficacy 1.17 (0.94, 1.44) 1.13 (0.98, 1.31)
Glaucoma outcome expectations 1.08 (0.99, 1.18) 1.08 (0.96, 1.21)
Newly prescribed glaucoma medications 1.17 (0.47, 2.91) 0.78 (0.36, 1.67)
Number of glaucoma medications 0.62 (0.39, 0.98)* 1.07 (0.65, 1.76)
Provider engages patient in collaborative goal setting at one or both visits 0.82 (0.46, 1.45) 0.44 (0.29, 0.65)***
Provider conducts an individualized assessment at one or both visits 0.99 (0.58, 1.69) 0.75 (0.49, 1.14)
Provider encourages patient to take medications at one or both visits 1.45 (0.80, 2.65) 1.84 (1.24, 2.73)**
Provider gives positive reinforcement about glaucoma medication taking 2.80 (1.44, 5.43)** 2.86 (1.76, 4.65)***
Total amount of glaucoma medication education provided at both visits 0.81 (0.65, 1.00) 1.18 (0.97, 1.44)
Total amount of glaucoma education provided at both visits 1.35 (1.03, 1.78)* 0.96 (0.75, 1.25)
Physician age 0.97 (0.94, 1.01) 0.98 (0.96, 1.00)
Physician gender-female 0.65 (0.31, 1.36) 0.83 (0.47, 1.49)
OR, Odds Ratio; 95%CI, 95%, Confidence Interval.
*P< 0.05, **P< 0.01, ***P< 0.001.
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Despite the limitations, this longitudinal pro-
spective cohort study provides important new find-
ings which indicate that providers giving patients
positive reinforcement about their medication
taking, educating patients about glaucoma and
encouraging patients to take their medications
were all positively associated with patient adherence
to glaucoma medications over an 8-month period.
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